ORIC Pharmaceuticals GAAP EPS of -$0.38 misses by $0.02 (ORIC:NASDAQ)
ORIC Pharmaceuticals (ORIC) Q2 GAAP EPS -$0.38 misses by $0.02; cash/investments $387.6M funds operations into 2H 2028.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
ORIC Pharmaceuticals (ORIC) Q2 GAAP EPS -$0.38 misses by $0.02; cash/investments $387.6M funds operations into 2H 2028.
ORIC Pharmaceuticals GAAP EPS of -$0.38 misses by $0.02 (ORIC:NASDAQ) | Seeking Alpha
ORIC Pharmaceuticals
press release
(
ORIC
): Q2 GAAP EPS of -$0.38
misses by $0.02
.
Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, which includes $59.9 million in net proceeds raised from healthcare specialist funds during the first quarter under the ATM (at-the-market) program. The
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Starwood Capital teams up with Trez Capital on U.S. residential land financing
Starwood Capital and Trez Capital partner on U.S. housing development loans, targeting $1B annually.
Athene Holding Ltd. 7.75%DP RT PFD E declares $0.4844 dividend (NYSE:ATH.PR.E)
Athene Holding declares a $0.4844 quarterly dividend with a 7.95% forward yield.
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.